Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Gtc Biotherapeutics Inc (GTCB) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Gtc Biotherapeutics Inc. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 904973.
Total stock buying since 2005: $16,254,981.
Total stock sales since 2005: $67,657.
Total stock option exercises since 2005: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2010 | 14,798 | $15,981 | 14,798 | $16,647 | 0 | $0 |
| 2009 | 3,387,851 | $3,625,000 | 0 | $0 | 0 | $0 |
| 2008 | 4,223,208 | $3,573,974 | 39,930 | $22,691 | 0 | $0 |
| 2007 | 7,342,765 | $9,007,772 | 0 | $0 | 0 | $0 |
| 2006 | 17,721 | $19,400 | 27,500 | $28,319 | 0 | $0 |
| 2005 | 9,000 | $12,854 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2010-02 | 14,798 | $15,981 | 0 | $0 | 0 | $0 |
| 2010-01 | 0 | $0 | 14,798 | $16,647 | 0 | $0 |
| 2009-11 | 3,387,851 | $3,625,000 | 0 | $0 | 0 | $0 |
| 2008-11 | 86,000 | $13,760 | 0 | $0 | 0 | $0 |
| 2008-03 | 100,400 | $48,192 | 39,930 | $22,691 | 0 | $0 |
| 2008-02 | 4,036,808 | $3,512,022 | 0 | $0 | 0 | $0 |
| 2007-12 | 44,565 | $39,418 | 0 | $0 | 0 | $0 |
| 2007-08 | 14,200 | $14,554 | 0 | $0 | 0 | $0 |
| 2007-03 | 24,000 | $24,000 | 0 | $0 | 0 | $0 |
| 2007-01 | 7,260,000 | $8,929,800 | 0 | $0 | 0 | $0 |
| 2006-12 | 0 | $0 | 7,500 | $8,220 | 0 | $0 |
| 2006-11 | 14,300 | $15,158 | 0 | $0 | 0 | $0 |
| 2006-09 | 3,421 | $4,242 | 0 | $0 | 0 | $0 |
| 2006-03 | 0 | $0 | 20,000 | $20,099 | 0 | $0 |
| 2005-11 | 3,000 | $4,824 | 0 | $0 | 0 | $0 |
| 2005-06 | 2,000 | $2,680 | 0 | $0 | 0 | $0 |
| 2005-05 | 4,000 | $5,350 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2010-02-09 | Scotland Richard A (Senior VP, Regulatory Affairs) | Buy | 14,798 | 1.08 | 15,981 |
| 2010-01-19 | Scotland Richard A (Senior VP, Regulatory Affairs) | Sale | 14,798 | 1.12 | 16,647 |
| 2009-11-02 | Lfb Biotechnologies S.a.s.u. (Director by Deputization) | Buy | 3,387,851 | 1.07 | 3,625,000 |
| 2008-11-21 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 86,000 | .16 | 13,760 |
| 2008-03-14 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 100,400 | .48 | 48,192 |
| 2008-03-12 | Liposky Gregory F (Senior VP, Operations) | Sale | 22,930 | .57 | 13,001 |
| 2008-03-12 | Woloshen Daniel S (Senior VP and General Counsel) | Sale | 17,000 | .57 | 9,690 |
| 2008-02-12 | Bechon Christian | Buy | 2,018,404 | .87 | 1,756,011 |
| 2008-02-12 | Lfb Biotechnologies S.a.s.u. | Buy | 2,018,404 | .87 | 1,756,011 |
| 2007-12-17 | Gray Mary Ann (Director) | Buy | 10,000 | .88 | 8,800 |
| 2007-12-17 | Woloshen Daniel S (Senior VP and General Counsel) | Buy | 1,200 | .89 | 1,068 |
| 2007-12-14 | Green John B (Senior VP and CFO) | Buy | 1,500 | .89 | 1,333 |
| 2007-12-14 | Liposky Gregory F (Senior VP, Operations) | Buy | 1,100 | .87 | 957 |
| 2007-12-14 | Meade Harry (SVP, Transgenic Research) | Buy | 10,000 | .90 | 9,000 |
| 2007-12-14 | Geraghty James A (Director) | Buy | 10,000 | .87 | 8,690 |
| 2007-12-13 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 10,765 | .89 | 9,570 |
| 2007-08-13 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 14,200 | 1.02 | 14,554 |
| 2007-03-14 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 24,000 | 1.00 | 24,000 |
| 2007-01-03 | Bechon Christian | Buy | 3,630,000 | 1.23 | 4,464,900 |
| 2007-01-03 | Lfb Biotechnologies S.a.s.u. | Buy | 3,630,000 | 1.23 | 4,464,900 |
| 2006-12-22 | Woloshen Daniel S (Senior VP and General Counsel) | Sale | 7,500 | 1.10 | 8,220 |
| 2006-11-06 | Cox Geoffrey F (President, CEO and Chairman) | Buy | 14,300 | 1.06 | 15,158 |
| 2006-09-29 | Geraghty James A (Director) | Buy | 2,621 | 1.24 | 3,250 |
| 2006-09-29 | Tuck Alan W (Director) | Buy | 800 | 1.24 | 992 |
| 2006-03-17 | Liposky Gregory F (Senior VP, Operations) | Sale | 20,000 | 1.00 | 20,099 |
| 2005-11-11 | Geraghty James A (Director) | Buy | 3,000 | 1.61 | 4,824 |
| 2005-06-01 | Tuck Alan W (Director) | Buy | 2,000 | 1.34 | 2,680 |
| 2005-05-16 | Green John B (SVP and CFO) | Buy | 1,000 | 1.39 | 1,390 |
| 2005-05-16 | Geraghty James A (Director) | Buy | 3,000 | 1.32 | 3,960 |
Insider trading activities including stock purchases, stock sales, and option exercises of GTCB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Gtc Biotherapeutics Inc (symbol GTCB, CIK number 904973) see the Securities and Exchange Commission (SEC) website.